Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A cluster-randomized trial of Vi-TT was conducted in Dhaka, Bangladesh, using JE vaccine as the control. A subset of 1,500 children were randomly selected on 2:1 basis (Vi-TT vs JE) to assess immune response. Blood was collected before vaccination, and on days 28, 545 and 730 post-vaccination and plasma anti-Vi-IgG response was measured. A robust, persistent antibody response was induced after single dose of Vi-TT, even after 2 years of vaccination. While there is no accepted serological antibody threshold of protection, analyzing the antibodies of children who received Vi-TT provides evidence that may later be useful in predicting population protection.

Original publication

DOI

10.1016/j.vaccine.2023.04.014

Type

Journal article

Journal

Vaccine

Publication Date

05/05/2023

Volume

41

Pages

3137 - 3140

Keywords

Bangladeshi children, CRT-TCV, Long-term immune response, Humans, Child, Typhoid Fever, Tetanus Toxoid, Salmonella typhi, Vaccines, Conjugate, Bangladesh, Immunoglobulin G, Typhoid-Paratyphoid Vaccines, Antibodies, Bacterial, Vaccination, Antibody Formation